# NM_005045.4(RELN):c.7887T>C (p.Pro2629=)

https://sugi.bio/variant/reln-p-pro2629

## Summary

**RELN p.Pro2629= (c.7887T>C)** is classified **Benign** in RELN (ClinVar, Multiple submitters, 12 submitters; last evaluated 2026-02-03). Common (popmax 28.7%, eas) — too common for a highly-penetrant pathogenic allele; Associated with Norman-Roberts syndrome.

**At a glance:** Benign · review: Multiple submitters · rsID rs56345626 · 12 submitters · 2 linked conditions · common (popmax 28.7%, eas) — too common for a highly-penetrant pathogenic allele

## For patients & families {#patients}

This is a change in the RELN gene that is classified as benign — not considered disease-causing, submitted by 12 submitters, and is linked to Norman-Roberts syndrome.

*Reference information, not medical advice, and not a prediction for any individual. A genetic counselor or clinician can interpret what it means for you and your family.*

**Support & next steps:** [Condition overview & support (NIH GARD)](https://rarediseases.info.nih.gov/diseases/0016780/index) · [Find a genetic counselor (NSGC)](https://findageneticcounselor.nsgc.org/).

## Identity {#identity}

| Field | Value |
| --- | --- |
| Gene | [RELN](https://sugi.bio/atlas/gene/RELN/) |
| Protein change (HGVS p.) | p.Pro2629= |
| Coding change (HGVS c.) | c.7887T>C |
| MANE Select transcript | [NM_005045](https://www.ncbi.nlm.nih.gov/nuccore/NM_005045) |
| dbSNP | [rs56345626](https://www.ncbi.nlm.nih.gov/snp/rs56345626/) |
| Variant type | single nucleotide variant |
| Location | chr7:103515417-103515417 (GRCh38) |
| ClinVar | [VCV130142](https://www.ncbi.nlm.nih.gov/clinvar/variation/130142/) |

**All HGVS expressions:** `NC_000007.13:g.103155864A>G`, `NC_000007.14:g.103515417A>G`, `NG_011877.2:g.479100T>C`, `NM_005045.4:c.7887T>C`, `NM_173054.3:c.7887T>C`

## Computational & population evidence {#evidence}

**Concordance:** Evidence sources **disagree** — common (popmax 28.7%, eas) — too common for a highly-penetrant pathogenic allele.

- **Missense predictors (AlphaMissense/REVEL/SaProt) do not apply** to this variant type — they score amino-acid substitutions only. For non-missense variants the computational signal comes from conservation (below), not from a missing predictor score.
- Conservation: phyloP -0.112, GERP -2.03, phastCons 0.005 — not a conserved position (phyloP < 0.1, ACGS BP7 cut)
- CADD: **PHRED 7.661**. No single ClinGen-calibrated threshold exists and the expert panels that use CADD disagree — GUCY2D/AIPL1 require ≥ 20.0 for an untranslated-region variant, ABCA4 ≥ 28.1 for a synonymous or indel variant, the Pulmonary Hypertension panel imports Pejaver 2022's missense-calibrated numbers, and the Antibody Deficiencies panel declines CADD entirely for PIK3CD. CADD v1.7 also incorporates Zoonomia phyloP, so it partly re-expresses the conservation above. *Descriptive; no threshold applied.*
- SpliceAI: **no splice effect predicted**. SpliceAI outputs four numbers per variant, not one: acceptor loss, donor loss, acceptor gain, donor gain (DS_AL / DS_DL / DS_AG / DS_DG). The release publishes its own filter rule, which we read from the dataset rather than assume: an allele is reported only if the largest of its four deltas reaches 0.2. This allele is not in the release, so all four of its deltas are under 0.2. No figure is shown because none was read: the bound is deduced from that absence. It is a result, not a gap in our data, and here that is proven rather than inferred: a different substitution at this very position, A>T, IS in the release and scores Δ0.99 acceptor gain, so SpliceAI evaluated this position and this allele was not among the ones that cleared the filter. *ClinGen's SVI treats the largest of the four as evidence against a splicing effect at or below 0.1, where it may support BP4, and as uninformative between 0.1 and 0.2. We cannot tell which applies here, so these SpliceAI data support neither BP4 nor PP3; that is a statement about this evidence alone, not about the variant's other evidence.*
- Population frequency (gnomAD v4.1): grpmax **28.7%** (eas) · FAF95 28.3% · FAF99 28.1% · 12,878/44,856 in the highest group · 294,272/1,613,810 alleles overall — common (popmax 28.7%, eas) — too common for a highly-penetrant pathogenic allele.

| Ancestry group | Allele frequency | 1 in |
| --- | --- | --- |
| East Asian (grpmax) | 28.7% | 3 |
| Finnish (not grpmax-eligible) | 21.1% | 5 |
| Middle Eastern | 19.9% | 5 |
| Remaining individuals (not grpmax-eligible) | 18.4% | 5 |
| European (non-Finnish) | 18.4% | 5 |
| Amish (not grpmax-eligible) | 18.1% | 6 |
| Ashkenazi Jewish (not grpmax-eligible) | 17% | 6 |
| South Asian | 15.9% | 6 |
| Admixed American | 15% | 7 |
| African / African-American | 13.1% | 8 |

*Computational predictors are not independent (ClinGen Variant Classification guidance): AlphaMissense (Cheng et al. 2023) carries the ACMG weight for missense and conservation (phyloP/GERP/phastCons) for non-missense; REVEL (Pejaver-2022 calibrated strength bands) and SaProt (Su et al. 2023, structure-aware, ClinVar-independent protein language model, raw LLR) are shown as orthogonal agreement signals, not additive. For frequency, the gnomAD v4.1 grpmax filtering allele frequency (FAF95) is ClinGen's designated BA1/BS1 input (gnomAD v4 guidance v3.0, June 2025); BA1/BS1 thresholds are disease-specific, not a blanket 5%. Predictions, not a clinical determination.*

## Gene constraint & dosage {#gene-context}

**RELN** population constraint: LOEUF 0.276, pLI 1, missense-Z 4.2857; ClinGen dosage — haploinsufficiency 0/3, triplosensitivity 0/3. *Lower LOEUF and higher pLI indicate a gene that tolerates loss-of-function poorly; ClinGen dosage is the curated haploinsufficiency call.*

Curated gene–disease validity (ClinGen):

- **lissencephaly with cerebellar hypoplasia** — Definitive (AR)
- **complex neurodevelopmental disorder** — Disputed (AD)

## Protein context {#protein}


**1 experimental structure(s)** (PDB): [8G21](https://www.rcsb.org/structure/8G21).

## What this gene does {#gene-function}

*Describes the biological roles of RELN (the gene this variant disrupts) — not effects measured for this specific variant. A damaging variant is expected to affect these functions and pathways; the degree depends on the variant.*


### Pathways affected {#pathways}

RELN participates in **1 Reactome pathway** (⚕ = disease pathway):

| Pathway (Reactome) | Evidence |
| --- | --- |
| [Reelin signalling pathway](https://reactome.org/content/detail/R-HSA-8866376) | other |

## Clinical significance {#significance}

**Benign** — review status Multiple submitters *(criteria provided, multiple submitters, no conflicts)*, last evaluated 2026-02-03.

**Submitter consensus:** conflicting (11 Benign, 1 Likely benign).

**Submission history:** 12 submissions (2015–2026); classifications have differed over time.

### Submitter classifications {#submitters}

| Submitter | Classification | Review | Method | Date |
| --- | --- | --- | --- | --- |
| PreventionGenetics, part of Exact Sciences | Benign | criteria provided, single submitter | clinical testing |  |
| Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen | Benign | no assertion criteria provided | clinical testing |  |
| Athena Diagnostics | Benign | criteria provided, single submitter | clinical testing | 2018-05-07 |
| Illumina Laboratory Services, Illumina | Benign | criteria provided, single submitter | clinical testing | 2018-01-12 |
| Breakthrough Genomics, Breakthrough Genomics | Benign | criteria provided, single submitter | not provided |  |
| Blueprint Genetics | Benign | criteria provided, single submitter | clinical testing | 2024-11-27 |
| Genetic Services Laboratory, University of Chicago | Likely benign | no assertion criteria provided | clinical testing |  |
| Clinical Genetics, Academic Medical Center | Benign | no assertion criteria provided | clinical testing |  |
| GeneDx | Benign | criteria provided, single submitter | clinical testing | 2015-03-03 |
| Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center | Benign | no assertion criteria provided | clinical testing |  |
| Mayo Clinic Laboratories, Mayo Clinic | Benign | criteria provided, single submitter | clinical testing | 2018-04-02 |
| Labcorp Genetics (formerly Invitae), Labcorp | Benign | criteria provided, single submitter | clinical testing | 2026-02-03 |

## Associated conditions {#conditions}

[Norman-Roberts syndrome](https://sugi.bio/atlas/disease/norman-roberts-syndrome/), [familial temporal lobe epilepsy 7](https://sugi.bio/atlas/disease/familial-temporal-lobe-epilepsy-7/).

**Reported phenotype names (ClinVar):** Norman-Roberts syndrome, not specified, Familial temporal lobe epilepsy 7, not provided, none provided, AllHighlyPenetrant, Lissencephaly 2 (Norman-Roberts type).

## Similar variants {#similar}

Related RELN variant pages (same residue, condition, or type): [RELN p.Pro2629Arg](/variant/reln-p-pro2629arg), [RELN p.Pro2629Leu](/variant/reln-p-pro2629leu), [RELN p.Pro2629Ala](/variant/reln-p-pro2629ala), [RELN c.3912+2T>G](/variant/reln-c-3912-plus-2t-g), [RELN c.7349+2T>C](/variant/reln-c-7349-plus-2t-c), [RELN p.Arg1622Ter](/variant/reln-p-arg1622ter), [RELN c.1893-3C>T](/variant/reln-c-1893-minus-3c-t), [RELN c.227-3C>T](/variant/reln-c-227-minus-3c-t).

### Data sources & attribution {#sources}

ClinVar (NCBI — public domain, built 2026-10-14); gnomAD v4.1 (Broad Institute, built 2026-10-15); AlphaMissense (Cheng et al. 2023, © Google DeepMind — CC BY 4.0, built 2026-01-27); REVEL (Ioannidis et al. 2016 — ODbL, built 2026-07-13); SaProt (Su et al. 2023 — MIT, built 2026-10-14); SpliceAI (Illumina — free for non-commercial use, built 2026-10-13); CADD (Rentzsch et al. 2019, University of Washington — free for non-commercial use, built 2026-10-10); Conservation (phyloP/phastCons/GERP) (UCSC hg38 470-way mammal (Hiller Lab) + Ensembl Compara, built 2026-07-12); gnomAD Non-coding Constraint (Gnocchi) (Chen et al. 2024, Broad Institute — CC0, built 2026-10-11); gnomAD Regional Missense Constraint (Broad Institute — CC0, built 2026-10-13); Pangolin (Zeng & Li 2022 — CC BY 4.0, built 2026-10-11); Repeat regions (UCSC — RepeatMasker, TRF, segmental duplications, built 2026-10-11); ClinGen (ClinGen, built 2026-09-22); UniProt (CC BY 4.0); Reactome / GO (CC BY 4.0, built 2026-09-23); MaveDB (per-record license, built 2026-10-11); CIViC (CC0, built 2026-09-22); Orphanet (Orphanet, built 2026-06-12)

*Primary record: NCBI ClinVar (variation 130142). Classifications reflect these databases as of the page's build date and may change. Free reference use — not medical advice; consult the primary submitters and a clinician.*